Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate

Cellectis SA of France hopes to begin clinical testing in the first half of this year with its gene edited product candidate in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This is the first IND filing for a gene edited allogeneic product candidate in the US.

UCART (Universal Chimeric Antigen Receptor T-cells) are 'off-the-shelf' allogeneic products, which means their production can be industrialized and standardized with consistent pharmaceutical release criteria, over time and from batch to...